Inovio Pharmaceuticals (formerly Inovio Biomedical) is electrifying the its vaccine delivery process. The firm's electroporation infusion therapy uses electrical pulses to open up cell membranes, thus optimizing the delivery of its DNA vaccines that can protect from cancers as well as chronic infectious diseases including HIV and hepatitis C. Its SynCon process identifies shared characteristics among different strains of similar viruses to help develop a universal flu vaccine that will be effective on most influenza strains, unlike traditional flu vaccines that are strain-specific. It also has a couple of anti-inflammatory drugs in its pipeline and some DNA-based animal growth hormones for livestock.